E2 ModeratePreliminaryPEM requiredObservationalPeer-reviewedReviewed
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
Øystein Fluge, Olav Mella, Ove Bruland et al. · PLoS ONE · 2011 · DOI
Quick Summary
In this pilot RCT, 30 ME/CFS patients received rituximab (a B-cell depleting antibody used in cancer and autoimmune disease) or placebo. Two-thirds of the rituximab group showed clinical improvement, with delayed response patterns consistent with autoimmune disease mechanisms. The placebo group had minimal response.
Why It Matters
This was the first RCT to suggest an immune (autoimmune) mechanism in ME/CFS with a therapeutic signal. The delayed response to B-cell depletion suggested ME/CFS might involve pathological antibodies. It triggered a large Phase III trial.
Observed Findings
- Two-thirds of rituximab-treated patients showed clinical improvement versus minimal response in placebo group
- Response patterns were delayed, consistent with autoimmune disease mechanisms
- Pilot RCT included 30 ME/CFS patients
- Phase III rituximab trial (Fluge et al. 2019) failed to replicate positive findings
Inferred Conclusions
- Pilot results suggest potential B-cell involvement in ME/CFS pathophysiology for a subset of patients
- Negative Phase III outcomes indicate pilot findings may not generalize or sustain across larger populations
- Rituximab's mechanism of action aligns with autoimmune hypothesis but clinical efficacy remains unproven
Remaining Questions
- What patient characteristics or biomarkers predict rituximab responders versus non-responders?
- Why did the Phase III trial fail to replicate pilot results—insufficient sample stratification, different patient populations, or absence of true effect?
- Are alternative B-cell targeting approaches more effective, or should research focus on other immune mechanisms in ME/CFS?
What This Study Does Not Prove
The Phase III rituximab trial (Fluge et al. 2019) was negative, failing to replicate these results. This pilot study, while historically important, should be interpreted in light of the negative phase III outcome.
Tags
Method Flag:PEM_DEFINEDSmall SampleNOT_REPLICATEDEXPLORATORYPEM Not DefinedWeak Case DefinitionExploratory Only
Symptom:Fatigue
Biomarker:CytokinesBlood Biomarker
Metadata
- DOI
- 10.1371/journal.pone.0026358
- Sample size
- 30 patients
- Control group
- Yes
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 7 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.